Gout – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) and characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from the chronic management of hyperuricemia with urate-lowering therapies and is not considered in this study. The aim of chronic treatment is to reduce the number and severity of acute flares, and damage to the affected joints. Xanthine oxidase inhibitors (XOIs) are the mainstay of chronic gout treatment, with generic allopurinol prescribed extensively. Krystexxa is a highly efficacious biological drug reserved for later lines of therapy. This report provides important insights into how these agents are used in the management of chronic gout and how practices are evolving.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed gout patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed gout patients?
- How has Krystexxa been integrated into the treatment algorithm, and what is its source of business?
- What percentage of gout patients receive drug therapy within one year of diagnosis, and how quickly What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of gout patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
- Markets covered: United States
- Key companies: Horizon Pharma, Takeda Pharmaceuticals, Cardinal Health
- Key drugs: Krystexxa, febuxostat, allopurinol, probenecid, probenecid / colchicine
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Gout - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Gout US February 2023
- Treatment Algorithms CDA Gout US 2023 Dashboard
Tej Pal, M.Pharm., is a senior healthcare research & data analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. He has authored several reports focusing on metabolic and renal indications. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.